Zacks Investment Research on MSN

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...
Yahoo Finance

aTyr Pharma, Inc. (ATYR)

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...